BMY’s robust launch portfolio, resilient free cash flow, and above-consensus growth outlook position it for outsized returns ...

Shares of this biotech giant have lost 16.3% year to date compared with the industry’s decline of 2.7%. The stock has also ...

Pharma/biotech giants Pfizer PFE and Bristol Myers BMY boast of a dominant position in the lucrative oncology space. Oncology ...

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and ...

Nivolumab plus chemotherapy significantly improved OS vs chemo alone in resectable NSCLC, per updated CheckMate-816 findings.

Opdivo Qvantig is not known to interact with other medications, herbs, supplements, foods, or alcohol. The manufacturer did not list any interactions in the drug’s prescribing information.

The FDA has approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma.

Opdivo + Yervoy cut cancer progression or death risk by 79% vs. chemo in first-line MSI-H/dMMR colorectal cancer patients. PFS at 12 months was 79% with Opdivo + Yervoy vs. 21% with chemo; median ...

The combination of Opdivo plus Yervoy was granted accelerated approval by the U.S. FDA in 2020 as a second-line treatment for patients with advanced HCC based on Phase 2 CheckMate -040 trial results.

PRINCETON, N.J., February 19, 2025--BMS Announces Opdivo® Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant ...

Opdivo hasn’t been reported to interact with other drugs. But this doesn’t mean that interactions aren’t possible. For example, new drugs may be developed that might interact with Opdivo.